Submit to Special Issue Submit Abstract to Special Issue Review for Gastroenterology Insights Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Feature Papers in Liver Research"

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Gastroenterology Insights (ISSN 2036-7422). This special issue belongs to the section "Liver".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 25254

Share This Special Issue

Special Issue Editor

Prof. Dr. David A. Gerber

E-Mail Website
Guest Editor

Department of Surgery, University of North Carolina, Chapel Hill, NC 27514, USA
Interests: hepatocellular carcinoma; liver transplantation; liver stem cells

Special Issue Information

Dear Colleagues,

Liver disease encompasses a broad and exciting area of investigation that intersects with multiple areas of ongoing research endeavors. This Special Issue is dedicated to exciting and informative investigations around malignancies of the liver. From the identification of biomarkers, drug discovery and therapeutic interventions to investigations of the molecular phenotypes of various liver pathologies, this field of study is rapidly changing.

This Special Issue aims to collect articles in cutting-edge areas of investigation involving liver cancer research, including those which could contribute towards translational solutions for world-wide health challenges associated with hepatic malignancies using innovative ideas and rigorous scientific methodologies. In the case of review articles, they could provide a synthesis of ideas and have the potential to lead to future innovations, while simultaneously creating novel frameworks capable of advancing our understanding of cancers of the liver. We encourage Editorial Board Members of the liver section to contribute feature papers reflecting the latest progress in their research field, or to invite leading experts to contribute.

Prof. Dr. David A. Gerber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastroenterology Insights is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

hepatocellular carcinoma
cholangiocarcinoma
fibrolamellar carcinoma
liver cancer
diagnosis
treatment

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review, Other

Open AccessArticle

Blood-Based Non-Invasive Tests of Hepatic Fibrosis in Autoimmune Hepatitis: Application among Selected Patients Leads to Higher Accuracy

and

Gastroenterol. Insights 2022, 13(3), 286-295; https://doi.org/10.3390/gastroent13030029 - 09 Sep 2022

Viewed by 1333

Abstract

Background. Assessment of liver fibrosis is essential to guide treatment in autoimmune hepatitis (AIH), but non-invasive tests (NITs) showed poor accuracy. Our study aims to evaluate the performance of NITs among different AIH presentations. Methods. Monocentric retrospective study among 122 AIH patients. NITs were compared to histological grading of liver fibrosis. We performed an accuracy analysis among acute (jaundice and/or transaminases > 10 times upper limit of normal) and non-acute patients. Results. A significant difference in the distribution of NIT values for each Ishak stage was found for spleen-diameter-to-platelet-count ratio (SD/PC) (p < 0.001), fibrosis-4-score (FIB-4) (p = 0.002), AST-to-ALT ratio (AAR) (p = 0.002), red-blood-cell-width-distribution-to-platelet-count ratio (RDW/PC) (p = 0.008) and AST-to-platelet-count ratio (APRI) (p = 0.029). The AUC for advanced fibrosis of SD/PC, FIB-4, RDW/PC, APRI and AAR were, respectively, 0.814, 0.770, 0.768, 0.708 and 0.694. The AUC of SD/PC, FIB-4 and APRI in non-acute subgroup were 0.902, 0.834 and 0.758, while in acute patients they were 0.754, 0.724 and 0.716. RDW/PC and AAR weren’t different among the two subgroups. Conclusions. For SD/PC, FIB-4 and APRI, diagnostic accuracy is higher in patients with non-acute presentation. In this context, SD/PC and FIB-4 showed an overall performance that could be of interest in clinical practice alongside other non-invasive techniques. Full article

(This article belongs to the Special Issue Feature Papers in Liver Research)

► Show Figures

Figure 1

Review

Jump to: Research, Other

Open AccessReview

Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation

Sonia Samuel

Ahmad Abulawi

and

Raza Malik

Gastroenterol. Insights 2023, 14(3), 249-270; https://doi.org/10.3390/gastroent14030018 - 29 Jun 2023

Cited by 1 | Viewed by 820

Abstract

Hepatitis C infection is a leading etiology of hepatic dysfunction and a major indication for liver transplantation due to the development of fibrosis, cirrhosis, and hepatocellular carcinoma. Nonalcoholic fatty liver disease (NAFLD) and, specifically, its subtype nonalcoholic steatohepatitis (NASH) is a rising cause of liver disease. It is predicted to surpass hepatitis C as a leading indication for transplant. The introduction of direct-acting antivirals (DAAs) decreased the prevalence of chronic hepatitis C infections, but the obesity epidemic and metabolic syndrome have increased the prevalence of NASH. Weight loss and dietary modifications are recommended NASH therapies, but unlike for hepatitis C, federally approved agents are lacking and currently under investigation. Clinical trials face many barriers in NASH treatment because of the difficulty of diagnosis and a lack of standardized and accurate clinical and histologic responses. Mortality and morbidity in NASH are heightened because of the presence of multiple comorbidities including cardiovascular disease, diabetes, and renal dysfunction. A liver transplant may be indicated, but a thorough screening of candidates, including a comprehensive cardiovascular assessment, is essential to ensuring successful outcomes pre- and post-transplant. Therapeutic agents for NASH are warranted before it becomes a significant and leading cause of morbidity and mortality worldwide. Full article

(This article belongs to the Special Issue Feature Papers in Liver Research)

► Show Figures

Figure 1

Open AccessReview

Clinical and Safety Evaluation of Liv.52 in Alcoholic Liver Disease: A Review

Uddagiri Venkanna Babu

and

Rajesh Kumawat

Gastroenterol. Insights 2022, 13(4), 377-386; https://doi.org/10.3390/gastroent13040037 - 13 Nov 2022

Cited by 1 | Viewed by 21343

Abstract

Alcoholic liver disease (ALD) has been a growing concern in developed and developing nations. Oxidative stress and lipid peroxidation are the most common cause of the development and progression of ALD. Due to paucity in the number and efficacy of hepatoprotective drugs currently available, and with the easy availability of natural therapy and herbal medicines, ALD is managed using a combination of pharmaceutical interventions and herbal medications. However, the effectiveness of these hepatoprotectives is controversial. Preclinical and clinical studies have demonstrated that Liv.52 modulates the lipotropic activity of hepatocytes, reduces inflammation, enhances alcohol and acetaldehyde metabolism, and protects the hepatic parenchyma by restoring the antioxidant levels of hepatocytes. Clinical studies further support that there is improvement in the subjective symptoms of patients as well as improvements in liver function test parameters. Studies suggest that Liv.52 is well tolerated and has no reported side effects. Full article

(This article belongs to the Special Issue Feature Papers in Liver Research)

► Show Figures

Figure 1

Other

Jump to: Research, Review

Open AccessCase Report

A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival

and

Gastroenterol. Insights 2023, 14(1), 38-44; https://doi.org/10.3390/gastroent14010005 - 12 Feb 2023

Cited by 1 | Viewed by 1301

Abstract

We report the case of a 68-year-old man with advanced hepatocellular carcinoma (HCC) with multiple bone metastases (BM) treated with tyrosine kinase inhibitors. Despite an insufficient disease control on BM with a progression free survival (PFS) of 6 months, sorafenib was not discontinued and multiple radiation therapy (RT) sessions with a palliative purpose were performed. Thanks to this aggressive radiotherapy approach in order to control the bone tumor burden, the patient has continued sorafenib for 34.6 months achieving an overall survival (OS) of 41.3 months. This result highlights the importance of a tailored management of patients with advanced HCC and the role of the RT for BM control, even if at lower cumulative radiation dose, for extending patient survival. Full article

(This article belongs to the Special Issue Feature Papers in Liver Research)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Feature Papers in Liver Research"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Review

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI